Log In
BCIQ
Print this Print this
 

ARGX-115

  Manage Alerts
Collapse Summary General Information
Company argenx N.V.
DescriptionAntibody targeting leucine-rich repeat containing 32 (LRRC32; GARP)
Molecular Target Leucine-rich repeat containing 32 (LRRC32) (GARP)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerUniversite catholique de Louvain

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$685.0M

0

$645.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/20/2016

$685.0M

0

$645.0M

11/03/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today